Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
DBV Technologies SA - American (DBVT)
NASDAQ:DBVT
RESEARCH TOOLSreports
Holding DBVT?
Track your performance easily
DBVT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.50 - $2.97
Previous Close$0.75
Volume130.66K
Average Volume (3M)43.58K
Market Cap
$73.15M
Enterprise Value$19.33M
Total Cash (Recent Filing)$66.21M
Total Debt (Recent Filing)$7.16M
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Oct 31, 2024EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding96,498,927
10 Day Avg. Volume59,700
30 Day Avg. Volume43,581
Standard Deviation0.28
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.65
Price to Sales (P/S)4.20
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.32
Enterprise Value/Gross Profit1.23
Enterprise Value/Ebitda-0.23
Forecast
1Y Price Target
$5.00Price Target Upside614.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
DBV Technologies SA - American News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 3 VITESSE trial remains on track to complete enrollment while DBV continues to make progress in getting the COMFORT Toddlers safety study started.
Financial PerformanceDBVT ended 2Q24 with $66M in cash, which provides sufficient runway into 1Q25.
Product PreferenceAnalysts continue to think Viaskin Peanut will be a preferred peanut allergy treatment in younger children.
Bears Say
Capital RequirementsAdditional capital will be needed to get Viaskin Peanut across the goal line in both the 1-3 and 4-7 year old populations.
Cost ConcernsXolair comes with the baggage of a black box warning for anaphylaxis and a steep price tag which can range from approximately $36K-$140K per year depending on the individual’s weight and baseline IgE.
Regulatory RisksXolair’s black box warning for anaphylaxis and steep price might limit its adoption.
---
Ownership Overview
30.44% Insiders
0.55% Mutual Funds
15.03% Other Institutional Investors
53.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DBVT FAQ
What was DBV Technologies SA - American’s price range in the past 12 months?
DBV Technologies SA - American lowest stock price was $0.50 and its highest was $2.97 in the past 12 months.
What is DBV Technologies SA - American’s market cap?
Currently, no data Available
When is DBV Technologies SA - American’s upcoming earnings report date?
DBV Technologies SA - American’s upcoming earnings report date is Oct 31, 2024 which is in 42 days.
How were DBV Technologies SA - American’s earnings last quarter?
DBV Technologies SA - American released its earnings results on Jul 30, 2024. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.447 by $0.107.
Is DBV Technologies SA - American overvalued?
According to Wall Street analysts DBV Technologies SA - American’s price is currently Undervalued.
Does DBV Technologies SA - American pay dividends?
DBV Technologies SA - American does not currently pay dividends.
What is DBV Technologies SA - American’s EPS estimate?
DBV Technologies SA - American’s EPS estimate is -$0.35.
How many shares outstanding does DBV Technologies SA - American have?
DBV Technologies SA - American has 96,498,924 shares outstanding.
What happened to DBV Technologies SA - American’s price movement after its last earnings report?
DBV Technologies SA - American reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.447. Following the earnings report the stock price went up 2.105%.
Which hedge fund is a major shareholder of DBV Technologies SA - American?
Among the largest hedge funds holding DBV Technologies SA - American’s share is Baker Bros Advisors LP. It holds DBV Technologies SA - American’s shares valued at 6M.
---
DBV Technologies SA - American Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (614.29% Upside)
$5.00 (614.29% Upside)
Hedge Fund Trend
Decreased
By 1.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.77%
12-Months-Change
Fundamentals
Return on Equity
-72.64%
Trailing 12-Months
Asset Growth
-47.50%
Trailing 12-Months
Company Description
DBV Technologies SA - American
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
---
DBVT Earnings Call
Q2 2024
0:00 / 0:00
---
DBVT Stock 12 Month Forecast
Average Price Target
$5.00
▲(614.29% Upside)
Technical Analysis
Best Analysts Covering DBVT
1 Year
1 Year Success Rate
5/22 ratings generated profit
1 Year Average Return
-30.26%
reiterated a buy rating 2 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 22.73% of your transactions generating a profit, with an average return of -30.26% per trade.
---